Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a
Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced
urothelial carcinoma that has specific changes in tumor genes. Patients must have previously
received treatment with chemotherapy that included a "platinum-containing agent" such as
cisplatin. The study will enroll in stages, with 15 patients in the first stage. More
patients will be added to the study if enough patients having beneficial responses are
observed. Mocetinostat will be administered using oral capsules three times each week (eg,
Monday, Wednesday and Friday). The study is designed to evaluate whether the number of
patients responding to treatment is substantially higher than would be expected with other
available treatments.